Regeneron Pharmaceuticals, Inc.REGN

Regeneron’s latest 10-Q shows a company still printing money, with $3.61 billion in revenue for the quarter ending 31 March 2026 and net income of $727.2 million. The operating engine is ticking over at $642.9 million, while the company’s balance sheet looks like the envy of the biotech world: $40.87 billion in assets against $9.45 billion in liabilities, and $2.96 billion in cash and equivalents. The cash machine is clearly working, but the real story is the concentration of risk in a single geography and a single franchise drug that still accounts for 26% of US revenue.

Regeneron isn’t a start-up; it’s a cash-generative machine that has spent $1.54 billion on R&D in the quarter, funded by a business model built around expensive medicines. The company’s website is a slick showcase of genetic medicines, CRISPR feats, and auditory gene therapies, complete with partner logos and clinical-trial bragging rights. But the balance sheet tells a plainer story: inventories sit at $3.10 billion, down only $26.6 million, which suggests the manufacturing flywheel is oiled but not yet sprinting. The company’s VelociSuite technologies are being marketed as the secret sauce for drug discovery, yet the earnings power still rides on EYLEA HD and EYLEA, products that are as exposed to US pricing politics as they are to scientific success.

For the quarter, Regeneron reported revenue of $3.61 billion, net income of $727.2 million, operating income of $642.9 million, diluted EPS of $6.75, and 107.7 million diluted shares outstanding. Assets totalled $40.87 billion, liabilities $9.45 billion, and stockholders’ equity stood at $31.42 billion. Cash and equivalents were $2.96 billion, with net cash from operating activities at $1.08 billion. Inventory fell by $26.6 million to $3.10 billion, while R&D expense was $1.54 billion. The company also flagged that certain customers accounted for more than 10% of total gross product revenue, and that US prices are generally higher than in Canada or Mexico, with the spectre of parallel imports looming.

The company’s product pages trumpet genetic medicines, CRISPR breakthroughs, and auditory gene therapies, but the filing data shows the business engine is still heavily reliant on EYLEA HD and EYLEA in the US. The 10-Q confirms that the company’s aggregate US sales of EYLEA HD and EYLEA represented 26% of total revenues in the quarter, down from 34% a year earlier, yet still a material concentration. The company’s cash generation remains robust, but the earnings base remains concentrated, and the board’s latest 8-K offers no surprises beyond the quiet confirmation that no major IPR&D charges are anticipated.

Regeneron’s SEC filings can be tracked via the company’s EDGAR index, while its latest 10-Q and submissions JSON provide the granular data behind the headline numbers. The company’s product and technology pages offer a glossy view of the pipeline, but the filings remain the definitive source for what the company actually collected, not what it promises. The evidence base does not include analyst forecasts, valuation commentary, or trading levels; it is limited to the named SEC filings and official company pages cited above.